In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 106-117

  Meletiadis, Joseph ^a   Mouton, Johan W ^b   Meis, Jacques F G M ^b   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DILUTION; DRUG POTENCY; DRUG POTENTIATION; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PRIORITY JOURNAL; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; SPECTROPHOTOMETRY;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PYRIMIDINES; SCEDOSPORIUM; TRIAZOLES;

EID: 12244250808     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.106-117.2003     Document Type: Article

References (48)

1. Bailey, E. M., D. J. Krakovsky, and M. J. Rybak. 1990. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10:146-153.
2. Balfour, J. A., and D. Faulds. 1992. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43:259-284.
3. Barchiesi, F., L. F. Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti, and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
4. Barriere, S. L. 1990. Pharmacology and pharmacokinetics of traditional systemic antifungal agents. Pharmacotherapy 10:134S-140S.
5. Berenbaum, M. C. 1985. The expected effect of a combination of agents: the general solution. J. Theor. Biol. 114:413-431.
6. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
7. Berenguer, J., J. L. Rodriguez-Tudela, C. Richard, M. Alvarez, M. A. Sanz, L. Gaztelurrutia, J. Ayats, J. V. Martinez-Suarez, et al. 1997. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Medicine (Baltimore) 76:256-265.
8. Bliss, C. I. 1939. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:585-615.
9. Carrillo, A. J., and J. Guarro. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2151-2153.
10. Cormican, M. G., and M. A. Pfaller. 1996. Standardization of antifungal susceptibility testing. J. Antimicrob. Chemother. 38:561-578.
11. Cuenca-Estrella, M., B. Ruiz-Diez, J. V. Martinez-Suarez, A. Monzon, and J. L. Rodriguez-Tudela. 1999. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:149-151.
12. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8:17-42.
13. D'Argenio, D. Z. 1990. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math Biosci. 99:105-118.
14. Drusano, G. L., D. Z. D'Argenio, W. Symonds, P. A. Bilello, J. McDowell, B. Sadler, A. Bye, and J. A. Bilello. 1998. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob. Agents Chemother. 42:2153-2159.
15. Espinel-Ingroff, A., F. Barchiesi, K. C. Hazen, J. V. Martinez-Suarez, and G. Scalise. 1998. Standardization of antifungal susceptibility testing and clinical relevance. Med. Mycol. 36:68-78.
16. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
17. Goldin, A., and N. Mantel. 1957. The employment of combination drugs in the chemotherapy of neoplasia: a review. Cancer Res. 17:635-654.
18. Gosbell, I. B., M. L. Morris, J. H. Gallo, K. A. Weeks, S. A. Neville, A. H. Rogers, R. H. Andrews, and D. H. Ellis. 1999. Clinical, pathologic and epidemiologic features of infection with Scedosporium prolificans: four cases and review. Clin. Microbiol. Infect. 5:672-686.
19. Graybill, J. R. 1996. The future of antifungal therapy. Clin. Infect. Dis. 22(Suppl. 2):S166-S178.
20. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
21. Greco, W. R., H. S. Park, and Y. M. Rustum. 1990. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 50:5318-5327.
22. Hindler, J. 1995. Antimicrobial susceptibility testing, p. 5.18.11-15.18.20. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, American Society for Microbiology Press, Washington, D.C.
23. Jackson, R. C. 1991. Synergistic and antagonistic drug interactions resulting from multiple inhibition of metabolic pathway, p. 363-408. In T. C. Chou, and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, New York, N.Y.
24. Kauffman, C. A., and P. L. Carver. 1997. Antifungal agents in the 1990s. Current status and future developments. Drugs 53:539-549.
25. Levasseur, L. M., W. R. Greco, Y. M. Rustum, and H. K. Slocum. 1997. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 40:495-505.
26. Meletiadis, J., J. F. Meis, J. W. Mouton, J. P. Donnelly, and P. E. Verweij. 2000. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J. Clin. Microbiol. 38:2949-2954.
27. Meletiadis, J., J. F. Meis, J. W. Mouton, J. L. Rodriquez-Tudela, J. P. Donnelly, and P. E. Verweij. 2002. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. 46:62-68.
28. Meletiadis, J., J. F. Meis, J. W. Mouton, and P. E. Verweij. 2001. Analysis of growth characteristics of filamentous fungi in different nutrient media. J. Clin. Microbiol. 39:478-484.
29. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
30. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2000. Comparison of spectrophotometric and visual reading of NCCLS method and evaluation of a colorimetric method based on the reduction of a soluble tetrazolium/formazan, XTT, for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
31. Meletiadis, J., J. W. Mouton, J. F. Meis, and P. E. Verweij. 2000. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin. Microbiol. Infect. 6:336-337.
32. Meletiadis, J., J. W. Mouton, J. L. Rodriguez-Tudela, J. F. Meis, and P. E. Verweij. 2000. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44:470-472.
33. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. Document M-38P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
34. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
35. Polak, A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355-370.
36. Prichard, M. N., L. E. Prichard, W. A. Baguley, M. R. Nassiri, and C. Shipman, Jr. 1991. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob. Agents Chemother. 35:1060-1065.
37. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
38. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
39. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
40. Ryder, N. S. 1992. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br. J. Dermatol. 126(Suppl. 39):2-7.
41. Ryder, N. S., and I. Leitner. 2001. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. 39:91-95.
42. Shenep, J. L., B. K. English, L. Kaufman, T. A. Pearson, J. W. Thompson, R. A. Kaufman, G. Frisch, and M. G. Rinaldi. 1998. Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin. Infect. Dis. 27:1388-1393.
43. Suhnel, J. 1990. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antivir. Res. 13:23-39.
44. Veldstra, H. 1956. Synergism and potentiation with special reference to the combination of structural analogues. Pharmacol. Rev. 8:339-387.
45. Verweij, P. E., N. J. Cox, and J. F. Meis. 1997. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur. J. Clin. Microbiol. Infect. Dis. 16:26-28.
46. Webb, J. L. 1963. Effect of more than one inhibitor, p. 66-79. Enzymes and metabolic inhibitors, vol. 1. Academic Press, New York, N.Y.
47. Webb, J. L. 1963. Effect of more than one inhibitor, p. 487-512. Enzymes and metabolic inhibitors, vol. 1. Academic Press, New York, N.Y.
48. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.